LOS ANGELES (Reuters) - A U.S. Food and Drug Administration advisory panel may call on Thursday for further restrictions on the use of anemia drugs in cancer patients, leading some investors to expect lower sales for Amgen Inc’s (AMGN.O: Quote, Profile, Research) top-selling Aranesp.
